Moscow Endocrine Plant, MEZ Endopharm

"Moscow Endocrine Plant" works in the field of circulation of medicines. The company occupies a strong position in the pharmaceutical market, and our products are recognizable and in demand. The company is developing dynamically, its equipment meets the necessary international standards.

History

2023: Creation of a factory for the production of pharmaceutical substances for 30 billion rubles

In July 2023, it became known about the start of the project for the construction of a plant for the production of active pharmaceutical substances in the Bryansk region. We are talking about the enterprise FSUE Endopharm, where it is planned to create about 1000 jobs.

The investment project is being implemented jointly with. Ministry of Industry and Trade The volume of investments is about 30 billion. rubles The project implementation period is no more than two years. We have already carried out all the necessary preliminary work, in the near future they will begin to select contractors for construction and installation work and purchase equipment, the Vkontakte governor of the Bryansk region wrote on his page in "" Alexander Bogomaz on July 7, 2023.

A factory for the production of pharmaceutical substances for 30 billion rubles is being created in the Bryansk region

This is a very important project for the Russian pharmaceutical industry, which will allow avoiding import dependence and producing vital and necessary drugs in a full cycle, "he said, adding that they are simultaneously preparing a raw material base, plant raw materials necessary for the production of analgesics, which is grown in Bryansk fields.

In turn, the press service of FSUE Endopharm reports that in the Pochep branch, the state-owned enterprise organizes "modern high-tech large-tonnage production of at least 60 items of domestic active pharmaceutical substances obtained by chemical or biotechnological synthesis, as well as from animal and vegetable raw materials."

By August 1, we expect a positive conclusion on the project documentation from the Glavgosexpertiza and immediately begin to select contractors for construction and installation work and equipment supply, - the words of Mikhail Fonarev, General Director of FSUE Endopharm, are quoted in the press release.[1]

2022

Obtain GMP Compliance Report

FSUE Moscow Endocrine Plant (FSUE Endopharm) received a conclusion on compliance with the GMP requirements of the Eurasian Economic Union for the Production of Veterinary Drugs. The conclusion confirms the compliance of the products with the established international safety and quality criteria. This was announced on November 22, 2022 by the head of the Department of Investment and Industrial Policy of Moscow, which is part of the Complex of Economic Policy and Property and Land Relations of the capital, Vladislav Ovchinsky.

GMP (Good Manufacturing Practice) is an international standard that establishes requirements for the production and quality control of medicines for humans and animals.

Obtaining an appropriate conclusion increases the export potential of the enterprise due to the possibility of bringing demanded medicines for veterinary use to the unified market of the EAEU. The Moscow Endocrine Plant, one of the city's pharmaceutical manufacturers, began production of the veterinary drug in the summer of 2022. The company plans to produce more than 100 thousand packages by the end of the year, - said Vladislav Ovchinsky.

The drug has already been launched on the Russian market and is used as a complex therapy as an analgesic. It is used for moderate and severe pain syndrome in the postoperative period, for injuries, diagnostic or therapeutic manipulations, including dental, and other non-communicable diseases. The manufacturer plans to bring injectable veterinary medicine for general anesthesia to the market by the end of 2022.

The head of the department recalled that in 2016, the Moscow Endocrine Plant was assigned the status of an industrial complex, which allows you to receive tax breaks and invest the saved funds in the development of production.

In addition, according to the offset contract that the city signed with the company in 2021, the investor must localize the production of 20 drugs in the city within two years: anti-glaucoma, antibacterial, analgesic, as well as antidepressants and antipsychotics. Moscow, in turn, guarantees the purchase of drugs for 1.1 billion rubles in eight years.

Start-up of veterinary product production

FSUE "Moscow Endocrine Plant" (FSUE "Endopharm") launched the production of the first veterinary drug in its assortment. The first batch has already been launched on the Russian market. This was announced on September 14, 2022 by the head of the Department of Investment and Industrial Policy of Moscow, which is part of the Complex of Economic Policy and Property and Land Relations of the capital, Vladislav Ovchinsky.

Pharmaceutical enterprises of the city produce products for the treatment of a large list of diseases. Every year, more and more of their own developments appear in the portfolio of companies, sometimes in completely new directions for them. One of the city's manufacturers, the Moscow Endocrine Plant, began producing medicines for animals in 2022 and has already brought its first drug for veterinary use to the market, "said Vladislav Ovchinsky.

The drug is used as a complex therapy for dogs and cats as an analgesic for moderate and severe pain syndrome in the postoperative period, for injuries, diagnostic or therapeutic manipulations, including dental, and other non-infectious diseases accompanied by pain syndrome.

Medicines for animals - a promising direction for the enterprise. We plan to expand the veterinary range. For example, by the end of 2022 we expect to bring to the market an injectable drug for general anesthesia. We are also considering the possibility of producing veterinary drugs within the framework of contract production, - said Mikhail Fonarev, General Director of FSUE Endopharm.

The city provides comprehensive support to the manufacturer. Since 2016, the company has the status of an industrial complex, which allows it to receive tax breaks and direct the saved funds to expand production and scientific developments.

In addition, in 2021, the city signed an offset contract with the Moscow Endocrine Plant. The volume of investments in it is a billion rubles. Under the contract, the investor must localize the production of 20 drugs in the city within two years: anti-glaucoma, antibacterial, analgesic, as well as antidepressants and antipsychotics. Moscow, in turn, guarantees the purchase of drugs for 1.1 billion rubles in eight years.

Permit to Expand and Upgrade the Laboratory Facility

The Moscow Endocrine Plant (FSUE Endopharm), subordinate to the Ministry of Industry and Trade of Russia, announced on August 31, 2022 that it had received permission to expand and modernize three floors of its laboratory complex in the Southeast administrative district of the capital. This will improve the quality of the company's products and expand the list of manufactured drugs.

A large enterprise pharmaceutical industries capitals will modernize almost 1.3 thousand square meters of its laboratory complex and allocate about 130 million for these purposes. As rubles a result, 88 new jobs will appear there. As of to data August 31, 2022, more than 75 percent of drugs produced by the Moscow Endocrine Plant are included in the list of vital and essential. The expansion of laboratory capacities will speed up incoming and releasing quality control of raw materials and finished products, and will also contribute to an increase in the range of domestic drugs - both original and created within the framework, import substitution said Mayor of Moscow economic politicians Vladimir Efimov, deputy for issues and property and land relations.

Illustration: mos.ru

The reconstruction project provides for the replacement of ceilings, the installation of ventilation and fire systems, equipping laboratories with high-tech equipment, the deputy mayor added.

In 2016, the company received the status of an industrial complex, thanks to which it began to receive tax breaks from the city and direct the saved funds to expand production and scientific development. For enterprises with special status, the regional part of income tax is 13.5 percent instead of 17, property tax is half as much and land tax is reduced by 80 percent.

In June 2022, the plant opened the Center for the Development of Biotechnological and Innovative Medicines in the Lefortovsky branch in the Sokolinaya Gora area. In August 2022, they are working on improving production technologies for more than 60 active pharmaceutical substances, as well as on the creation of three drugs.

The pharmaceutical manufacturer continues to receive support from the city. So, in February 2021, the Moscow Endocrine Plant and the Moscow government signed an offset contract.

Under the terms of the contract, the company will localize the production of 20 medicines in the capital within two years. The company will produce anti-glaucoma, antibacterial, analgesic drugs, antidepressants and antipsychotics. The planned volume of investments for these purposes is estimated at a billion rubles. As of August 31, 2022, the city has already signed five offsets with manufacturers of medicines, medical products and products for dairy kitchens. The capital is actively working on over 10 contracts in the field of pharmaceuticals, transport, housing and communal services and the production of medical devices, noted the head of the Department of Investment and Industrial Policy of Moscow, Vladislav Ovchinsky.

From July 1, 2022, the requirements for the conclusion of offsets were simplified. The minimum investment under such contracts decreased by 10 times - up to 100 million rubles. In addition, it became possible to sign offsets together with two or more constituent entities of the Russian Federation with a total investment of at least 400 million rubles.

Investment projects implemented by the enterprise are aimed at solving the problems of reducing import dependence, producing domestic drugs in a full cycle and uninterrupted provision of citizens with demanded and socially significant medicines in sufficient volume, noted the general director of FSUE Endopharm, Mikhail Fonarev.

Opening of the Center for the Development of Biotechnological and Innovative Drugs

At the end of June 2022, a center for the development of biotechnological and innovative drugs was launched in Moscow. It was launched on the basis of the Moscow Endocrine Plant (MEZ) in the Lefortovsky branch. Read more here

2021: Investment of 1.2 billion rubles in the creation of a laboratory and warehouse building

On March 1, 2021, it became known that the Moscow Endocrine Plant will invest 1.2 billion rubles in the creation of a laboratory and warehouse building. The building with a total area of ​ ​ 15 thousand square meters. m will appear on Novokhokhlovskaya street and will be associated with existing buildings, according to the official portal of the capital's mayor.

As the chief architect of Moscow, Sergei Kuznetsov, explains, by the beginning of March 2021, it is planned to build, reconstruct and technically re-equip an industrial complex for the production of drugs on the basis of the Moscow Endocrine Plant. The production itself is waiting for modernization, and the emergence of this laboratory and warehouse complex is one of its stages, he added.

Moscow Endocrine Plant invests 1.2 billion rubles in the construction of a laboratory and warehouse building

The construction and reconstruction of the industrial complex on the basis of the Moscow Endocrine Plant will take place in three stages. Technical re-equipment and reconstruction of the laboratory complex of the enterprise, as well as the site for the production of soft dosage forms is provided.

The corresponding project was agreed by the Moscow Architecture Committee. Glavgosexpertiza of Russia approved it on February 17, 2021.

It is worth noting that both federal subsidies and benefits from the city government contribute to the modernization of the enterprise. Thus, the Moscow Endocrine Plant was given the status of an industrial complex, which provides a number of preferences: reducing the regional part of the income tax, as well as land and property tax, - said the head of the Department of Investment and Industrial Policy of Moscow Alexander Prokhorov.

The Moscow City Hall allocated a land plot to the Moscow Endocrine Plant for the construction of a laboratory-administrative-warehouse complex back in 2016. It is planned to put the facility into operation in 2022. By March 1, 2021, the project is in the "active stage," according to the portal of the mayor of Moscow.^[2]

2020: Launch of a new line for the production of liquid and soluble drugs

On January 22, 2020 pharmaceutical , the company Moscow launched a line for the production of liquid and soluble drugs, as well as eye drops. The workshop with a total area of ​ ​ almost 3 thousand square meters is located on the territory of the plant in the Southeast administrative district of Moscow. This was announced on January 23, 2020 by the Moscow DIiPP.

The pharmaceutical industry of the capital industry employs more than 30 large and medium-sized manufacturers and 9 research organizations. In total, more than 10.5 thousand people are employed at these enterprises in January 2020, investments in fixed assets amount to 3.8 billion rubles, said Deputy Mayor of Moscow in the Government of Moscow on economic policy and property and land relations Vladimir Efimov

The vice-mayor stressed that the Moscow Endocrine Plant is the largest Moscow pharmaceutical manufacturer by the number of employees (as of January 23, 2020 - 1080 people). This is the only enterprise in Russia producing narcotic and psychotropic drugs for oncology, the plant produces 91 names of drugs.

File:Запуск новой линии по производству жидких и растворимых лекарственных препаратов.jpeg

{{quote 'author = noted the head of the Department of Investment and Industrial Policy of Moscow Alexander Prokhorov' The plant receives the support of the Moscow Government - in 2016 the company was given the status of an industrial complex. The volume of benefits provided is 27.2 million rubles. The volume of investments in the launched production line amounted to 1.23 billion rubles. Created 90 new jobs, }}

In 2018, FSUE MEZ transferred 2 branches, in the reconstruction of which it is planned to invest about 9 billion rubles by 2023: in Moscow (launch in 2022) and the Bryansk region (launch in 2023).

2020

After the project to launch the Lefortovo branch in Moscow, more than 800 high-tech jobs will be created by 2023. Tax deductions to the city budget will amount to about 100 million rubles annually. At the site of the Lefortovsky branch, it is planned to create a workshop for the production of injection emulsion solutions as part of the import substitution program.

Notes